Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trials crawled time : 08:20 save search
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100
Published: 2022-09-10 (Crawled : 08:20) - prnewswire.com
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
| Email alert
Add to watchlist
skyrizi trials skin week 100 results
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Published: 2022-09-10 (Crawled : 08:20) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
cosentyx trials novartis
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.